Oregon's wooing pulls Genentech north for $400M facility

Last week Genentech took the wraps off its $400-million manufacturing and distribution complex outside Portland, OR.

The company is expected to begin the manufacturing approval process later this month. Manufacturing follows its earlier set-up of fill/finish and distribution operations. A local press report says that 50 manufacturing employees will join the 250 warehouse and packaging workers already at the 75-acre site.

The company says it hopes to start commercial production early next year, and eventually plans to produce cancer treatments Rituxan, Avastin and Herceptin, the report says.

Governor Ted Kulongoski is credited with a lengthy and generous courtship leading to the knot-tying that resulted in Genentech's first facility outside of California. The state anted up $23 million in property tax exemptions over 15 years plus $5 million in training assistance.

The South San Francisco-based biotech giant has manufacturing plants in Vacaville and Oceanside. Portland, for its part, now boasts a big biotech in addition to the multi-facility presence of chip-maker Intel.

- here's the story

Suggested Articles

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot. 

The FDA recently asked five drug manufacturers to recall the commonly used diabetes med metformin. With COVID-19 raging, is metformin just the start?

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.